Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05322577 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
A Phase 1 study of Gastric Cancer and Gastroesophageal-junction Cancer, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT05322577: Active Phase 1 study of Gastric Cancer and Gastroesophageal-junction Cancer, sponsored by Amgen.
NCT05322577 is a Phase 1 study of Gastric Cancer and Gastroesophageal-junction Cancer that is active but no longer recruiting, run by Amgen. The registered enrollment target is 72 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05322577, a Phase 1 study of Gastric Cancer and Gastroesophageal-junction Cancer, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objectives of this study are to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies, and to evaluate the efficacy of bemarituzumab in combination with S-1 and oxaliplatin (SOX) and nivolumab as assessed by objective response.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG CAPOX
- DRUG Bemarituzumab
- DRUG SOX
Study Locations (20)
Gifu
- Gifu University Hospital - Gifu
- Ogaki Municipal Hospital - Ogaki-shi
Gunma
- Gunma University Hospital - Maebashi
- Gunma Prefectural Cancer Center - Ota-shi
Hiroshima
- Hiroshima City Hiroshima Citizens Hospital - Hiroshima
- Hiroshima University Hospital - Hiroshima
Kanagawa
- St Marianna University Hospital - Kawasaki-shi
- Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center - Yokohama
New York
- Northport Veterans Affairs Medical Center - Northport
Aichi-ken
- Fujita Health University Hospital - Toyoake-shi
Aomori
- Hirosaki University Hospital - Hirosaki-shi
Chiba
- Chiba University Hospital - Chiba
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2022-05-17 |
| Est. Completion | 2026-08-12 |
| Phase | Phase 1 |
What the registry record for NCT05322577 still lists
NCT05322577 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT05322577 names 20 study sites across 16 states, led by Gifu, Gunma, Hiroshima.
Frequently Asked Questions
What is clinical trial NCT05322577 about?
NCT05322577 is a clinical study titled "A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.". The main objectives of this study are to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies, and to evaluate the efficacy of bemarituzumab in combination with S-1 and oxaliplatin (SOX) and nivolumab as assessed by objective response.
What is the current status of trial NCT05322577?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2022-05-17. Estimated completion is 2026-08-12.
What conditions does trial NCT05322577 study?
This clinical trial studies the following conditions: Gastric Cancer, Gastroesophageal-junction Cancer.
What interventions are being tested in trial NCT05322577?
The interventions under investigation include: Nivolumab (DRUG), CAPOX (DRUG), Bemarituzumab (DRUG), SOX (DRUG).
Who is sponsoring clinical trial NCT05322577?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05322577 being conducted?
This trial has 20 study locations across New York, Aichi-ken, Aomori, Chiba, Ehime. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05322577's enrollment target sits among peer trials
72 99th of 153 higher than 54 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI